Quick Answer
Forte Biosciences, Inc. reported Stockholders Equity of $60.99 million for the year ending 2025.
- Forte Biosciences, Inc. showed an increase of +16.2% in Stockholders Equity from 2024 to 2025.
- This data is from Forte Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$132.92 million | Q2 2017: $88.57 million | Q3 2017: $80.12 million | Q1 2018: $59.68 million | Q2 2018: $46.09 million | Q3 2018: $47.67 million | Q1 2019: -$1.92 million | Q2 2019: -$2.55 million | Q3 2019: -$3.24 million | Q1 2020: -$6.77 million | Q2 2020: $24.88 million | Q3 2020: $20.32 million | Q1 2021: $54.70 million | Q2 2021: $49.91 million | Q3 2021: $43.65 million | Q1 2022: $40.05 million | Q2 2022: $38.21 million | Q3 2022: $42.84 million | Q1 2023: $32.95 million | Q2 2023: $24.88 million | Q3 2023: $40.41 million | Q1 2024: $28.69 million | Q2 2024: $16.96 million | Q3 2024: $9.37 million | Q1 2025: $38.43 million | Q2 2025: $98.61 million | Q3 2025: $84.10 million.
- Over the full 12 years of available data (2014 to 2025), Forte Biosciences, Inc.'s Stockholders Equity has grown by 186.6%.
- Historical annual values: Fiscal year 2025: $60.99 million | Fiscal year 2024: $52.48 million | Fiscal year 2023: $35.31 million | Fiscal year 2022: $38.82 million | Fiscal year 2021: $41.55 million | Fiscal year 2020: $58.98 million | Fiscal year 2019: -$4.77 million | Fiscal year 2018: -$736.0 thousand | Fiscal year 2017: $71.08 million | Fiscal year 2016: -$124.42 million | Fiscal year 2015: -$92.33 million | Fiscal year 2014: -$70.44 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: